Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years

Antonio Agostini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6528-7140; OpenAlex author ID A5090981936. Sources: OpenAlex.

Their work

Papers
15 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
65
Papers, trials and grants by year

2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: 3 papers · 2025: 4 papers · 2026: 2 papers

Papers 15

  1. Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibition in Pancreatic Cancer First author DOI 10.34133/cancomm.0030↗
  2. High-fat diet imprints a macrophage-tumor CAMP-P2RX7 axis driving pancreatic cancer initiation, plasticity and metastasis Co-author DOI 10.64898/2026.02.10.703309↗
  3. Local ablation disrupts immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217327↗
  4. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Co-author DOI 10.1038/s41586-025-08721-9↗
  5. Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic… Co-author DOI 10.1186/s13046-024-03238-x↗
  6. The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration. Co-author DOI 10.1186/s13046-024-03263-w↗
  7. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. Co-author DOI 10.1038/s41467-024-54975-8↗
  8. Weighted gene co-expression network analysis reveals key stromal prognostic markers in pancreatic cancer. First author DOI 10.1038/s41598-024-82563-9↗
  9. Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC. Co-author DOI 10.3389/fimmu.2024.1341079↗
  10. CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. Co-author DOI 10.1038/s41416-022-02028-6↗
  11. Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer. Co-author DOI 10.1186/s12967-023-04733-z↗
  12. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy. Co-author DOI 10.3390/ijms24119313↗
  13. Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and a promising therapeutic target Co-author DOI 10.21203/rs.3.rs-2095432/v1↗
  14. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with a… Co-author DOI 10.1136/jitc-2021-002876↗
  15. Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response. First author DOI 10.3389/fmed.2021.793144↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Carmine Carbone · 15 shared papers, 2021–2026 · strength 2.62
  2. Giampaolo Tortora · 11 shared papers, 2021–2026 · strength 1.88
  3. Vincenzo Corbo · 11 shared papers, 2021–2026 · strength 1.88
  4. Geny Piro · 11 shared papers, 2021–2026 · strength 1.83
  5. Francesco De Sanctis · 7 shared papers, 2021–2026 · strength 1.21
  6. Alessia Caggiano · 5 shared papers, 2022–2026 · strength 0.86
  7. Aldo Scarpa Scarpa · 5 shared papers, 2021–2025 · strength 0.75
  8. Francesca Lupo · 4 shared papers, 2024–2025 · strength 0.70
  9. Alberto Larghi · 4 shared papers, 2021–2025 · strength 0.59
  10. Claudio Luchini · 3 shared papers, 2024–2026 · strength 0.53
  11. Rita Teresa Lawlor · 3 shared papers, 2023–2025 · strength 0.47
  12. Lisa Salvatore · 2 shared papers, 2024–2025 · strength 0.42
  13. Vincenzo Bronte · 2 shared papers, 2025–2026 · strength 0.40
  14. Giuseppe Quero · 3 shared papers, 2021–2023 · strength 0.39
  15. Sergio Alfieri · 3 shared papers, 2021–2023 · strength 0.39
  16. Chiara Musiu · 2 shared papers, 2024–2025 · strength 0.38
  17. Gabriella Lionetto Lionetto · 2 shared papers, 2024–2025 · strength 0.38
  18. Salvatore Paiella · 2 shared papers, 2024–2025 · strength 0.38
  19. Claudio Sette · 2 shared papers, 2021–2026 · strength 0.34
  20. Giuseppe Malleo · 2 shared papers, 2025 · strength 0.34
  21. Roberto Salvia · 2 shared papers, 2025 · strength 0.34
  22. Sabrina L. D’Agosto · 2 shared papers, 2024–2025 · strength 0.32
  23. Lisa Veghini · 2 shared papers, 2024–2025 · strength 0.32
  24. Elena Fiorini · 2 shared papers, 2024–2025 · strength 0.32
  25. Francesco Spallotta · 2 shared papers, 2021–2025 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.